Amevive Lyophilisate For Solution For Injection 15Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Amevive: Lyophilisate for solution for injection (15mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

ALEFACEPT (a la FA cept) is used to treat adult patients with moderate or severe chronic plaque psoriasis.

In-Depth Information
Select a Medication

Amevive 15mg Powder for Injection

NDC: 004690021
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Psoriasis

Sometimes used for but not FDA approved for the following conditions:
Psoriatic Arthritis

Storage Information
Protect from light
Store between 36 to 46 degrees F
Amevive 15mg Powder for Injection

Reported Side Effects for Amevive 15mg Powder for Injection

Skin Rash Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Hives Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Heart Attack Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Angioedema Incidence:
0.2%*
Severity: SEVERE
Onset: RAPID
Upset Stomach Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Vomiting Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Itching Incidence:
1.0-10.0%*
Severity: MILD
Onset: RAPID
Sore Throat Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Cough Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Secondary Malignancy Incidence:
1.3%*
Severity: MODERATE
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
1.7%*
Severity: MODERATE
Onset: DELAYED
Antibody Formation Incidence:
3.0-72.0%*
Severity: MODERATE
Onset: DELAYED
Chills Incidence:
6.0%*
Severity: MILD
Onset: RAPID
Lightheadedness Incidence:
>10.0%*
Severity: MILD
Onset: EARLY
Low Lymphocytes Incidence:
10.0-42.0%*
Severity: MODERATE
Onset: DELAYED
Injection Site Reaction Incidence:
16.0%*
Severity: MILD
Onset: RAPID
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Amevive

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5